EGFR and urinary bladder cancer: In the genomic analysis of 413 bladder cancers with genomic sequence data from The Cancer Genome Atlas (TCGA) (http://www.cbioportal.org), we identified discrete EGFR amplification (5%) and PTEN deletion (5%); however, cases harboring both EGFR and PTEN alteration as observed in the current MIBC case were extremely rare, suggesting that these two alterations are mutually exclusive.